EPCR Selection for Hematopoietic Stem Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for expanding human hematopoietic stem cells (HSCs) ex vivo face challenges due to the scarcity of HSCs and the unreliable expression of markers like CD38 and CD49f in culture conditions, limiting the purification and functional analysis of these cells.
Innovation Solution
Selecting and culturing Endothelial Protein C Receptor (EPCR)+ cells from a starting population of stem and progenitor cells to expand them, utilizing EPCR as a stable surface marker for identifying and enriching HSCs, and using cell expanding factors like UM171 and cytokines to enhance expansion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional HSC markers (CD38, CD49f) are used for purification, then initial isolation can achieve up to 10% purity, but marker reliability deteriorates during ex vivo culture
Solution Approach 1:
The patent changes the identification parameter from traditional markers (CD38, CD49f) to EPCR marker, which maintains stable expression during ex vivo culture. This parameter substitution resolves the reliability issue while preserving measurement precision for HSC identification and purification.
2Productivity
If HSC expansion is attempted using current methods, then cell numbers can be increased, but purification quality deteriorates due to marker unreliability
Solution Approach 1:
By switching to EPCR as the selection marker, the patent maintains manufacturing precision (purification quality) while achieving productivity (expansion capacity). The EPCR+ cell population can be expanded ex vivo while maintaining marker stability and purification quality.
3Measurement precision
If rare HSCs are isolated from cord blood, then initial purity can reach 10%, but functional analysis is hampered by cell scarcity
Solution Approach 1:
The patent performs preliminary purification using EPCR marker to isolate HSCs with high purity, then expands these purified cells ex vivo before functional analysis. This preliminary purification followed by expansion resolves the contradiction between purification level and available cell number for functional studies.
Solution Approach 2:
Changing the marker from traditional parameters to EPCR enables both high purification level and sufficient cell quantity. The stable EPCR expression allows purification to 10% or higher purity while maintaining cell viability for subsequent expansion and functional analysis.
4Quantity of substance
If ex vivo culture is used to expand HSCs, then cell availability increases, but marker reliability deteriorates limiting functional dissection
Solution Approach 1:
The patent changes the measurement parameter from unstable markers (CD38, CD49f) to EPCR marker that maintains reliable expression during ex vivo culture. This enables both increased cell quantity through expansion and maintained measurement precision for functional dissection of HSC mechanisms.
Data Source
AI summary
It is provided a method of expanding ex vivo hematopoietic stem cells (HSC), the method comprising selecting a population of Endothelial Protein C Receptor (EPCR)+ HSC, culturing the selected HSC thereby expanding said EPCR+ HSC and the use of the expanded EPCR+ HSC for stem cells transplantation.